Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2022, with a specific reporting date of January 19, 2022. The document serves as a transaction notification regarding dealings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific share transactions executed by senior executives.
| Instrument | Transaction Price | Exchange |
|---|---|---|
| Ordinary Shares (GBP) | £16.3120 | London Stock Exchange (XLON) |
| American Depositary Shares (USD) | $45.0600 | New York Stock Exchange (XNYS) |
Material Changes
The filing reports no material changes to the company's operations or financial position. The only changes reported are increases in the notional interest of specific executives in GSK shares or ADSs. These increases resulted from the automatic re-investment of dividends paid to shareholders on January 13, 2022, under the Company's Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of routine executive compensation-related share acquisitions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were automatic dividend re-investments, not open-market purchases or sales by executives.
- Participants: Transactions involved 14 senior executives, including the CEO (Ms. E. Walmsley), CFO (Mr. I. Mackay), and Chief Scientific Officer (Dr. H. Barron).
- Timing: All transactions occurred on January 17, 2022, following the dividend payment date of January 13, 2022.
- Volume: Individual transaction volumes were relatively small, ranging from 41 ADSs to 2,058 Ordinary Shares per executive.
- Financial Data: This document does not provide company-level financial performance data; investors should refer to the most recent Form 20-F or quarterly earnings release for that information.